Emergent Biosolutions (EBS) Upgraded to “Buy” by Goldman Sachs Group

Emergent Biosolutions (NYSE:EBS) was upgraded by equities researchers at Goldman Sachs Group from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Friday, Marketbeat Ratings reports. The brokerage currently has a $75.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $60.00. Goldman Sachs Group’s target price would indicate a potential upside of 15.67% from the company’s current price.

Several other equities analysts have also commented on EBS. Cantor Fitzgerald set a $62.00 price target on Emergent Biosolutions and gave the company a “buy” rating in a research note on Tuesday, August 28th. Chardan Capital raised their price target on Emergent Biosolutions from $53.00 to $57.00 and gave the company a “buy” rating in a research note on Friday, August 3rd. Argus raised their price target on Emergent Biosolutions to $70.00 and gave the company an “average” rating in a research note on Tuesday, September 11th. They noted that the move was a valuation call. Cowen restated a “hold” rating and set a $49.00 price target on shares of Emergent Biosolutions in a research note on Wednesday, August 29th. Finally, Zacks Investment Research upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $60.00 price target on the stock in a research note on Tuesday, July 10th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $65.00.

EBS stock traded up $0.98 during midday trading on Friday, reaching $64.84. The company’s stock had a trading volume of 714,919 shares, compared to its average volume of 313,268. The company has a quick ratio of 4.15, a current ratio of 5.59 and a debt-to-equity ratio of 0.01. Emergent Biosolutions has a 1 year low of $36.38 and a 1 year high of $67.24. The firm has a market cap of $3.24 billion, a price-to-earnings ratio of 34.13, a PEG ratio of 1.33 and a beta of 1.27.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, November 1st. The biopharmaceutical company reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.07). Emergent Biosolutions had a return on equity of 15.09% and a net margin of 16.55%. The business had revenue of $173.70 million during the quarter, compared to analysts’ expectations of $185.16 million. During the same quarter in the previous year, the business earned $0.73 EPS. The business’s revenue for the quarter was up 16.3% on a year-over-year basis. Research analysts expect that Emergent Biosolutions will post 2.4 EPS for the current year.

In other news, Director Ronald Richard sold 7,893 shares of the firm’s stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $60.02, for a total transaction of $473,737.86. Following the transaction, the director now owns 21,063 shares in the company, valued at $1,264,201.26. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Fuad El-Hibri sold 36,318 shares of the firm’s stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $55.98, for a total value of $2,033,081.64. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 187,522 shares of company stock worth $11,293,890. Insiders own 16.50% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. grew its stake in Emergent Biosolutions by 20.2% in the second quarter. BlackRock Inc. now owns 5,372,711 shares of the biopharmaceutical company’s stock valued at $271,268,000 after purchasing an additional 901,882 shares during the last quarter. Renaissance Technologies LLC grew its stake in Emergent Biosolutions by 10.6% in the second quarter. Renaissance Technologies LLC now owns 2,066,511 shares of the biopharmaceutical company’s stock valued at $104,338,000 after purchasing an additional 198,600 shares during the last quarter. Northern Trust Corp grew its stake in Emergent Biosolutions by 11.3% in the second quarter. Northern Trust Corp now owns 1,150,184 shares of the biopharmaceutical company’s stock valued at $58,072,000 after purchasing an additional 117,098 shares during the last quarter. Rice Hall James & Associates LLC grew its stake in Emergent Biosolutions by 18.1% in the second quarter. Rice Hall James & Associates LLC now owns 1,141,021 shares of the biopharmaceutical company’s stock valued at $57,610,000 after purchasing an additional 174,614 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Emergent Biosolutions by 2.3% in the second quarter. Bank of New York Mellon Corp now owns 755,948 shares of the biopharmaceutical company’s stock valued at $38,167,000 after purchasing an additional 16,801 shares during the last quarter. Institutional investors own 83.12% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Read More: Trading Strategy Examples and Plans

Analyst Recommendations for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply